Zacks Investment Research Downgrades GRIFOLS S A/S (GRFS) to Hold
According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain. “
A number of other equities analysts have also recently issued reports on GRFS. BidaskClub cut shares of GRIFOLS S A/S from a hold rating to a sell rating in a research report on Wednesday, January 30th. Berenberg Bank lowered shares of GRIFOLS S A/S from a buy rating to a hold rating in a research report on Friday, February 8th. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company. GRIFOLS S A/S currently has a consensus rating of Hold and an average target price of $19.00.
GRIFOLS S A/S (NASDAQ:GRFS) last announced its quarterly earnings data on Thursday, February 28th. The biotechnology company reported $0.25 EPS for the quarter. The firm had revenue of $1.40 billion during the quarter. GRIFOLS S A/S had a net margin of 12.35% and a return on equity of 15.49%. On average, equities analysts predict that GRIFOLS S A/S will post 1.26 earnings per share for the current fiscal year.
A number of institutional investors have recently added to or reduced their stakes in GRFS. Schonfeld Strategic Advisors LLC grew its stake in GRIFOLS S A/S by 30.5% during the first quarter. Schonfeld Strategic Advisors LLC now owns 130,600 shares of the biotechnology company’s stock worth $2,626,000 after buying an additional 30,500 shares during the period. One Wealth Advisors LLC acquired a new position in shares of GRIFOLS S A/S during the first quarter worth $110,000. Morgan Stanley lifted its position in shares of GRIFOLS S A/S by 24.7% during the first quarter. Morgan Stanley now owns 1,105,978 shares of the biotechnology company’s stock worth $22,241,000 after purchasing an additional 219,132 shares in the last quarter. Man Group plc lifted its position in shares of GRIFOLS S A/S by 47.5% during the first quarter. Man Group plc now owns 1,452,471 shares of the biotechnology company’s stock worth $29,209,000 after purchasing an additional 467,645 shares in the last quarter. Finally, Advisors Asset Management Inc. lifted its position in shares of GRIFOLS S A/S by 40.8% during the first quarter. Advisors Asset Management Inc. now owns 5,108 shares of the biotechnology company’s stock worth $103,000 after purchasing an additional 1,479 shares in the last quarter. Hedge funds and other institutional investors own 19.01% of the company’s stock.
GRIFOLS S A/S Company Profile
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.
Featured Article: FAANG Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.